Hexima CEO, Michael Aldrige, spoke with Stockhead as part of their V-Con video conference series focused on biotechs. V-Con is Stockhead’s investing focused video conference series, bringing you expert insights, panel discussions and presentations from leading analysts, listed small caps and industry players.
Mr Aldridge, spoke about Hexima’s place in the anti-infectives space, our lead drug #pezadeftide being the first in a new class of antifungal agents and our path forward in clinical trials.
View the Stockhead interview here → V-Con Interview